Cerenome (PSTV) Common Equity (2010 - 2026)
Plus Therapeutics (PSTV) posted quarterly Common Equity of $12.0 million for Q1 2026, up 150.59% year-over-year from $4.8 million in Q1 2025, and up 199.32% quarter-over-quarter from $4.0 million in Q4 2025.
Cerenome (PSTV) Common Equity (2010 - 2026) Analysis & Trends
Plus Therapeutics (PSTV) has reported Common Equity for 17 consecutive years, with $12.0 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Common Equity rose 150.59% year-over-year to $12.0 million; the TTM figure through Mar 2026 stood at $12.0 million (up 150.59% YoY), while the FY2025 annual figure was $4.0 million, up 144.65% from the prior year.
- Common Equity advanced to $12.0 million in Q1 2026 per PSTV's latest filing, from $4.0 million in the prior quarter.
- Across five years, Common Equity topped out at $14.6 million in Q1 2022 and bottomed at -$23.6 million in Q1 2025.
- Historically, Common Equity has averaged $1.3 million across 5 years, with a median of $2.7 million in 2023.
- Annual changes were most pronounced in 2024 — Common Equity tumbled 563.87% — and 2025, when it surged 197.68%.
- Plus Therapeutics' Common Equity stood at $6.4 million in 2022, then slumped by 120.92% to -$1.3 million in 2023, then sank by 563.87% to -$8.9 million in 2024, then surged by 144.65% to $4.0 million in 2025, then surged by 199.32% to $12.0 million in 2026.
- Business Quant data shows PSTV's Common Equity at $12.0 million in Q1 2026, $4.0 million in Q4 2025, and $5.1 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 6.76 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 5.17 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.35 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 757.49 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 9.79 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 22.38 Bn |
| 10 | Cerenome | 28.07 Mn | 19.48 Mn | - | 5.46 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 11.96 Mn |
| Dec 31, 2025 | 4.00 Mn |
| Sep 30, 2025 | 5.05 Mn |
| Jun 30, 2025 | 3.03 Mn |
| Mar 31, 2025 | -23.64 Mn |
| Dec 31, 2024 | -8.95 Mn |
| Sep 30, 2024 | -5.17 Mn |
| Jun 30, 2024 | -7.63 Mn |
| Mar 31, 2024 | -4.84 Mn |
| Dec 31, 2023 | -1.35 Mn |
| Sep 30, 2023 | 2.62 Mn |
| Jun 30, 2023 | 2.66 Mn |
| Mar 31, 2023 | 2.68 Mn |
| Dec 31, 2022 | 6.45 Mn |
| Sep 30, 2022 | 11.40 Mn |
| Jun 30, 2022 | 9.68 Mn |
| Mar 31, 2022 | 14.64 Mn |
| Dec 31, 2021 | 10.84 Mn |
| Sep 30, 2021 | 14.76 Mn |
| Jun 30, 2021 | 11.95 Mn |